Literature DB >> 2323306

Effects of sublingually given naloxone in opioid-dependent human volunteers.

K L Preston1, G E Bigelow, I A Liebson.   

Abstract

To determine whether sublingual naloxone could precipitate withdrawal in opioid-dependent subjects, naloxone was administered in increasing doses (0-8 mg in four or six sessions conducted over 2 days) to six heroin abusers and three methadone (30 mg/day, p.o.) maintenance patients. Two or three sessions were conducted per day with 2- to 2.5-h intervals between same-day sessions. Naloxone precipitated withdrawal in two of six heroin abusers and in all three methadone subjects. Naloxone is sufficiently absorbed sublingually to precipitate abstinence in dependent subjects, but naloxone doses up to 1-2 mg can be administered sublingually to opioid abusers/addicts without precipitating withdrawal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2323306     DOI: 10.1016/0376-8716(90)90136-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  16 in total

Review 1.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.

Authors:  James Rosado; Sharon L Walsh; George E Bigelow; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2007-05-22       Impact factor: 4.492

3.  Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.

Authors:  Kelly E Dunn; Frederick S Barrett; George E Bigelow
Journal:  Addict Behav       Date:  2018-03-28       Impact factor: 3.913

4.  Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Authors:  Jermaine D Jones; Maria A Sullivan; Suzanne K Vosburg; Jeanne M Manubay; Shanthi Mogali; Verena Metz; Sandra D Comer
Journal:  Addict Biol       Date:  2014-07-25       Impact factor: 4.280

5.  Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.

Authors:  Angela N Duke; Christopher J Correia; Sharon L Walsh; George E Bigelow; Eric C Strain
Journal:  Psychopharmacology (Berl)       Date:  2010-06-25       Impact factor: 4.530

6.  Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.

Authors:  Sharon L Walsh; Paul A Nuzzo; Shanna Babalonis; Victoria Casselton; Michelle R Lofwall
Journal:  Drug Alcohol Depend       Date:  2016-03-14       Impact factor: 4.492

7.  Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.

Authors:  Debra S Harris; John E Mendelson; Emil T Lin; Robert A Upton; Reese T Jones
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  Narrative review: buprenorphine for opioid-dependent patients in office practice.

Authors:  Lynn E Sullivan; David A Fiellin
Journal:  Ann Intern Med       Date:  2008-05-06       Impact factor: 25.391

Review 9.  Buprenorphine use in pregnant opioid users: a critical review.

Authors:  Michael Soyka
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

Review 10.  Practical considerations for the clinical use of buprenorphine.

Authors:  Hendree E Jones
Journal:  Sci Pract Perspect       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.